SURMOUNT-5 trial data (2025) and broader real-world reports indicate tirzepatides dual GIP/GLP-1 mechanism produces appetite suppression comparable to or faster than semaglutide at equivalent weight-loss doses
To maximize results in the first month: Be patient as sustainable weight loss takes time
Remember, your well-being is our top priority, and we are here to support you every step of the way
Without the medications appetite-suppressing effects, individuals may find it harder to control their food intake, making it important to continue healthy habits learned during treatment
This medication binds to GLP-1 receptors, stimulating insulin release from the pancreas and reducing glucagon secretion
Headaches are a possible side effect of GLP-1 receptor agonists, and some people may experience migraine attacks while taking GLP-1 drugs